Trial Profile

A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Efficacy and Safety of Intravenous CXA-201 With That of Meropenem in Complicated Intraabdominal Infections.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ceftolozane/tazobactam (Primary) ; Meropenem; Metronidazole
Indications Gram-negative infections; Intra-abdominal infections; Pseudomonal infections
Focus Registrational; Therapeutic Use
Sponsors Cubist Pharmaceuticals

Most Recent Events

12 May 2019 This trial has been completed in spain as per European Clinical Trials Database record (EudraCT2011-002119-27)
12 May 2019 This trial has been completed in spain as per European Clinical Trials Database record (EudraCT2011-002119-27)
20 Dec 2016 Results of two studies (ASPECT-cIAI and ASPECT-cUTI) published in the Journal of Antimicrobial Chemotherapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com